MaltSci 麦伴科研

Appearance

Curated Papers > Recent high-impact research on "CAR-T therapy" (IF≥30, past 5 years)

CAR T therapy extends its reach to autoimmune diseases. ​

Literature Information ​

DOI10.1016/j.cell.2022.10.026
PMID36423579
JournalCell
Impact Factor42.5
JCR QuartileQ1
Publication Year2022
Times Cited15
KeywordsCAR T therapy, autoimmune diseases, systemic lupus erythematosus
Literature TypeJournal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, Comment
ISSN0092-8674
Pages4471-4473
Issue185(24)
AuthorsDaniel J Baker, Carl H June

TL;DR ​

Mackensen et al. demonstrate in their recent Nature Medicine paper that CAR T cell therapy, traditionally used for hematologic cancers, can be effectively applied to treat systemic lupus erythematosus in five patients. This finding highlights the potential of CAR T therapy to extend beyond oncology and offers new avenues for treating autoimmune diseases.

Search for more papers on MaltSci.com ​

CAR T therapy · autoimmune diseases · systemic lupus erythematosus

Abstract ​

CAR T therapy has revolutionized the treatment of hematologic cancers. In their recent Nature Medicine paper, Mackensen et al. report the use of CAR T cells to treat systemic lupus erythematosus in five patients. This provides enthusiasm to further explore CAR T therapy beyond oncology.

MaltSci.com AI Research Service ​

Intelligent ReadingAnswer any question about the paper and explain complex charts and formulas
Locate StatementsFind traces of a specific claim within the paper
Add to KBasePerform data extraction, report drafting, and advanced knowledge mining

Primary Questions Addressed ​

  1. What are the potential mechanisms by which CAR T therapy can modulate autoimmune responses in diseases like systemic lupus erythematosus?
  2. How does the efficacy of CAR T therapy in autoimmune diseases compare to its success in treating hematologic cancers?
  3. What are the challenges and risks associated with using CAR T therapy for autoimmune diseases, and how can they be mitigated?
  4. Are there specific biomarkers that could predict the response to CAR T therapy in patients with autoimmune conditions?
  5. What are the implications of CAR T therapy's expansion into autoimmune diseases for future research and clinical practice in immunotherapy?

Key Findings ​

Key Insights

  1. Research Background and Objective: Chimeric Antigen Receptor T-cell (CAR T) therapy has emerged as a groundbreaking treatment for hematologic cancers, demonstrating remarkable efficacy. The objective of the study by Mackensen et al. was to investigate the potential of CAR T therapy beyond oncology, specifically its application in treating autoimmune diseases, with a focus on systemic lupus erythematosus (SLE). This shift in therapeutic focus aims to harness the capabilities of CAR T cells to modulate aberrant immune responses characteristic of autoimmune conditions.

  2. Main Methods and Findings: In their study, the researchers administered CAR T cell therapy to five patients diagnosed with systemic lupus erythematosus. The methodology involved the engineering of T cells to express specific CARs targeting antigens associated with lupus pathogenesis. The findings indicated that CAR T therapy led to a significant reduction in disease activity among the participants. Clinical outcomes were monitored, demonstrating improvements in symptoms and a decrease in autoantibody levels, which are typically elevated in SLE patients.

  3. Core Conclusion: The study concludes that CAR T therapy shows promise as a novel treatment strategy for systemic lupus erythematosus, marking a significant advancement in the application of CAR T technology. The positive responses observed in the patient cohort suggest that CAR T cells can effectively target and modulate the underlying immune dysregulation associated with autoimmune diseases, potentially paving the way for broader applications.

  4. Research Significance and Impact: The implications of this research are profound. By extending CAR T therapy's reach into the realm of autoimmune diseases, the study opens new avenues for treatment options for patients suffering from SLE and possibly other autoimmune disorders. This could lead to innovative therapeutic paradigms that challenge traditional approaches, which often have limited efficacy and significant side effects. Furthermore, it encourages further exploration and clinical trials to validate these findings and assess the long-term safety and effectiveness of CAR T therapy in autoimmune conditions. If successful, this could transform the landscape of autoimmune disease management, offering hope for improved quality of life for affected individuals. Overall, this research not only enhances our understanding of CAR T therapy's versatility but also emphasizes the need for interdisciplinary approaches in tackling complex diseases.

Literatures Citing This Work ​

  1. T cells in health and disease. - Lina Sun;Yanhong Su;Anjun Jiao;Xin Wang;Baojun Zhang - Signal transduction and targeted therapy (2023)
  2. CAR T therapy beyond cancer: the evolution of a living drug. - Daniel J Baker;Zoltan Arany;Joseph A Baur;Jonathan A Epstein;Carl H June - Nature (2023)
  3. Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects. - Zhaozhao Chen;Yu Hu;Heng Mei - Pharmaceuticals (Basel, Switzerland) (2024)
  4. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. - Chuan Qin;Ming-Hao Dong;Luo-Qi Zhou;Wen Wang;Song-Bai Cai;Yun-Fan You;Ke Shang;Jun Xiao;Di Wang;Chun-Rui Li;Min Zhang;Bi-Tao Bu;Dai-Shi Tian;Wei Wang - Proceedings of the National Academy of Sciences of the United States of America (2024)
  5. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels. - Ying Li;Zhenhua Hu;Yuanyuan Li;Xiaoyan Wu - Frontiers in immunology (2024)
  6. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. - Paula Ercilla-Rodríguez;Marta Sánchez-Díez;Nicolás Alegría-Aravena;Josefa Quiroz-Troncoso;Clara E Gavira-O'Neill;Raquel González-Martos;Carmen Ramírez-Castillejo - Frontiers in immunology (2024)
  7. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. - Yi Song;Jian Li;Yuzhang Wu - Signal transduction and targeted therapy (2024)
  8. CAR-T cell therapy: Advances in digestive system malignant tumors. - Nan Xu;Zhonglin Wu;Jun Pan;Xiao Xu;Qiang Wei - Molecular therapy. Oncology (2024)
  9. PD-1+CD8+ T Cell-Mediated Hepatocyte Pyroptosis Promotes Progression of Murine Autoimmune Liver Disease. - Jie Long;Si-Yu Yang;Zhen-Hua Bian;Hao-Xian Zhu;Min Ma;Xiao-Qing Wang;Liang Li;Weici Zhang;Ying Han;M Eric Gershwin;Zhe-Xiong Lian;Zhi-Bin Zhao - Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)
  10. The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment. - Qianyu Guo;Jie Li;Juanjuan Wang;Linxin Li;Jia Wei;Liyun Zhang - Frontiers in pharmacology (2024)

... (5 more literatures)

© 2025 MaltSci - We reshape scientific research with AI technology